Adjuvant capecitabine after CRT improves survival in locally advanced nasopharynx

October 25, 2022Jason HarrisTreatment with adjuvant capecitabine following concurrent chemoradiotherapy resulted in superior failure-free survival compared with observation and CRT for patients with l

Updated on: October 17,2023 240

Adjuvant capecitabine after CRT improves survival in locally advanced nasopharynx

October 25, 2022Jason HarrisTreatment with adjuvant capecitabine following concurrent chemoradiotherapy resulted in superior failure-free survival compared with observation and CRT for patients with l

Updated on:October 17,2023 240

Camrelizumab Plus Nab-Paclitaxel Showcases Antitumor Activity in Platinum-Resistant Urothelial

September 30, 2022Ryan ScottThe combination of camrelizumab and nab-paclitaxel produced encouraging responses in patients with platinum-resistant, unresectable locally advanced or metastatic urothelia

Updated on: October 17,2023 63

Camrelizumab Plus Nab-Paclitaxel Showcases Antitumor Activity in Platinum-Resistant Urothelial

September 30, 2022Ryan ScottThe combination of camrelizumab and nab-paclitaxel produced encouraging responses in patients with platinum-resistant, unresectable locally advanced or metastatic urothelia

Updated on:October 17,2023 63

Multicenter Review Supports TKI Use in Patients With mRCC and Bone Metastases

September 20, 2022Megan HollaschAn analysis of patterns of care and outcomes for patients with metastatic renal cell carcinoma with bone metastases supported the role of TKIs as the standard of care.&

Updated on: October 17,2023 20

Multicenter Review Supports TKI Use in Patients With mRCC and Bone Metastases

September 20, 2022Megan HollaschAn analysis of patterns of care and outcomes for patients with metastatic renal cell carcinoma with bone metastases supported the role of TKIs as the standard of care.&

Updated on:October 17,2023 20

Cilta-cel Provides Durable Responses in Lenalidomide-Refractory Myeloma After 1 to 3 Prior Lines

August 28, 2022Kristi RosaCiltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.

Updated on: October 17,2023 25

Cilta-cel Provides Durable Responses in Lenalidomide-Refractory Myeloma After 1 to 3 Prior Lines

August 28, 2022Kristi RosaCiltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.

Updated on:October 17,2023 25

DetermaIO Assay Helps Inform Benefit With Single-Agent Immunotherapy in Advanced NSCLC

November 22, 2022Caroline SeymourThe score of the 27-gene Determa immune-oncology assay demonstrated a correlation with overall survival and progression-free survival in patients with advanced non–sma

Updated on: October 17,2023 34

DetermaIO Assay Helps Inform Benefit With Single-Agent Immunotherapy in Advanced NSCLC

November 22, 2022Caroline SeymourThe score of the 27-gene Determa immune-oncology assay demonstrated a correlation with overall survival and progression-free survival in patients with advanced non–sma

Updated on:October 17,2023 34

3-Week Course of Radiotherapy May Offer Greater Convenience for Patients With Soft Tissue Sarcoma

December 29, 2022Jason HarrisModerately hypofractionated preoperative radiotherapy did not increase risk for major wound complication in patients with soft tissue sarcomas, according to findings from

Updated on: October 17,2023 137

3-Week Course of Radiotherapy May Offer Greater Convenience for Patients With Soft Tissue Sarcoma

December 29, 2022Jason HarrisModerately hypofractionated preoperative radiotherapy did not increase risk for major wound complication in patients with soft tissue sarcomas, according to findings from

Updated on:October 17,2023 137

Maveropepimut-S Plus Pembrolizumab and Cyclophosphamide Shows Early Promise in R/R DLBCL

February 13, 2023Kristi RosaThe combination of maveropepimut-S, pembrolizumab, and intermittent low-dose cyclophosphamide elicited responses in patients with relapsed or refractory diffuse large B-cel

Updated on: October 17,2023 178

Maveropepimut-S Plus Pembrolizumab and Cyclophosphamide Shows Early Promise in R/R DLBCL

February 13, 2023Kristi RosaThe combination of maveropepimut-S, pembrolizumab, and intermittent low-dose cyclophosphamide elicited responses in patients with relapsed or refractory diffuse large B-cel

Updated on:October 17,2023 178

Key Factors to Consider in the Management of Tumor Lysis Syndrome

February 22, 2023Brittany LovelyFor patients with aggressive malignant tumors and high tumor burden, onco- logic emergencies such as tumor lysis syndrome emerge as a disease symptom or a treat- ment-r

Updated on: October 15,2023 27

Key Factors to Consider in the Management of Tumor Lysis Syndrome

February 22, 2023Brittany LovelyFor patients with aggressive malignant tumors and high tumor burden, onco- logic emergencies such as tumor lysis syndrome emerge as a disease symptom or a treat- ment-r

Updated on:October 15,2023 27

PD-1/VEGFR-2 Inhibitor Combo Shows Durable Responses in Nasopharyngeal Carcinoma

February 10, 2023Ashling WahnerThe combination of camrelizumab and apatinib led to long-term antitumor activity with manageable toxicities in patients with recurrent or metastatic nasopharyngeal carci

Updated on: October 15,2023 284

PD-1/VEGFR-2 Inhibitor Combo Shows Durable Responses in Nasopharyngeal Carcinoma

February 10, 2023Ashling WahnerThe combination of camrelizumab and apatinib led to long-term antitumor activity with manageable toxicities in patients with recurrent or metastatic nasopharyngeal carci

Updated on:October 15,2023 284

AFM24 Plus Atezolizumab Shows Acceptable Safety, Early Activity in EGFR+ Solid Tumors

January 14, 2023Ryan ScottA doublet comprised of the bispecific innate cell engager AFM24 and atezolizumab had a tolerable safety profile and elicited responses in patients with advanced EGFR-expressi

Updated on: October 15,2023 163

AFM24 Plus Atezolizumab Shows Acceptable Safety, Early Activity in EGFR+ Solid Tumors

January 14, 2023Ryan ScottA doublet comprised of the bispecific innate cell engager AFM24 and atezolizumab had a tolerable safety profile and elicited responses in patients with advanced EGFR-expressi

Updated on:October 15,2023 163

AstraZeneca to Discontinue Moxetumomab Pasudotox in US for Hairy Cell Leukemia

January 13, 2023Chris RyanMoxetumomab pasudotox-tdfk will be permanently discontinued in the United States market for the treatment of relapsed/refractory hairy cell leukemia.Hairy Cell Leukemia (Kate

Updated on: October 15,2023 168

AstraZeneca to Discontinue Moxetumomab Pasudotox in US for Hairy Cell Leukemia

January 13, 2023Chris RyanMoxetumomab pasudotox-tdfk will be permanently discontinued in the United States market for the treatment of relapsed/refractory hairy cell leukemia.Hairy Cell Leukemia (Kate

Updated on:October 15,2023 168

Fox Chase Physician Wins Best Poster Award at Breast Cancer Meeting for Research on Surgery to

May 26, 2023Fox Chase Cancer CenterAustin D. Williams, MD, MSEd, of Fox Chase Cancer Center, received the Best Poster Award at the recent 24th Annual Meeting of the American Society of Breast Surgeons

Updated on: October 15,2023 26

Fox Chase Physician Wins Best Poster Award at Breast Cancer Meeting for Research on Surgery to

May 26, 2023Fox Chase Cancer CenterAustin D. Williams, MD, MSEd, of Fox Chase Cancer Center, received the Best Poster Award at the recent 24th Annual Meeting of the American Society of Breast Surgeons

Updated on:October 15,2023 26